Preventive Medication Use among Adults Aged 40 and over in the United States: National Health and Nutrition Examination Survey, 2015–2018

Abdulkarim M. Meraya

Department of Pharmacy Practice, Faculty of Pharmacy, Jazan University, Jazan P.O. Box 114-45124, Saudi Arabia; ameraya@jazanu.edu.sa

Abstract: Objectives: 1. To estimate the prevalence of preventive medication use among adults in the United States (US); 2. To identify the socioeconomic, demographic and clinical factors associated with preventive prescription medication use; 3. To identify the diagnoses associated with preventive prescription medication use. Methods: Data from two cycles of the National Health and Nutrition Examination Survey, 2015–2016 and 2017–2018, are analyzed. Results: Among US adults aged 40 years or older (N = 7634), 31% use a preventive medication. Specifically, 27% of them use aspirin and 9% use other preventive prescription medications. Among those who use other preventive prescription medications, 27% report using one of the cardiovascular agents and 24% reported using anticoagulants and/or antiplatelet agents. High percentages of preventive prescription medication users report using medications to prevent heart attacks/myocardial infarctions (25%) or blood clots (23%). Uninsured adults are less likely to use preventive medications (OR: 0.656; p-value = 0.009) as compared with their counterparts with private insurance. On the other hand, older adults and those with diabetes, heart disease, arthritis and hypertension are more likely to use preventive medications. Furthermore, past smokers and adults who never smoked are more likely to use preventive medications as compared with those who currently smoke. Conclusion: Policies are needed to increase access to preventive care for uninsured adults. Further research needs to review the benefits and harms of the chronic use of preventive medication among older adults in the US.

Keywords: preventive; prescription medications; chronic diseases; NHANES; aspirin

1. Introduction

Preventive pharmacotherapy is widely used in the United States (US) [1–3]. Prescribers in the US use preventive medications either as primary prevention strategies to prevent chronic physical conditions before they occur, or as secondary prevention strategies to prevent complications from existing chronic physical conditions [1–3]. Common preventive medications including aspirin and lipid-lowering agents are among the most prescribed medications in the US [1–4]. These medications are used to prevent the occurrence or the complications of cardiovascular diseases in individuals at high-risk or who currently have the disease [2]. Preventive medications are not only used to prevent cardiovascular disease, but also to prevent migraines, cancer, type 2 diabetes mellitus, osteoporosis, gout and others [5–8].

In 2012, 52% of US adults aged 45–75 years reported the use of aspirin for the primary or secondary prevention of cardiovascular disease [3]. From 2011–2012, 28% of US adults aged 40 and over reported using lipid-lowering medications, and the percentage increased among individuals with cardiovascular disease (70%) or diabetes (63%) [1]. Antiplatelets, glucose-lowering drugs, antimigraine drugs and selective estrogen receptor modulators are also widely used as preventive therapies in the US [4–8]. In the US, previous studies have focused on the preventive medications for cardiovascular disease; however, a comprehensive review of the prevalence of preventive prescription medication use is lacking [2].
Moreover, little is known about the socioeconomic and demographic factors associated with preventive medication use.

Therefore, this study had three objectives: 1. To estimate the prevalence of preventive medication use among adults in the US; 2. To identify the socioeconomic, demographic and clinical factors associated with preventive medication use; and 3. To identify the diagnoses associated with preventive prescription medication use.

2. Materials and Methods

This is a retrospective cross-sectional study using data from two cycles of the National Health and Nutrition Examination Survey (NHANES), 2015–2016 and 2017–2018. The NHANES is conducted by US National Center for Health Statistics, Centers for Disease Control and Prevention to provide nationally representative statistics for the US population. The NHANES provides information on the health and nutritional statuses of children and adults in the US. In this study, demographic data and data on medical conditions and prescription medications were used to estimate the prevalence of preventive medication use among adults. The data used in this study are publicly available at https://www.cdc.gov/nchs/nhanes/ (accessed on 5 February 2022).

2.1. Study Sample

The study sample consisted of adults aged 40 years or older with no missing data on preventive medication use (N = 7634). The total number of individuals in the selected two NHANES cycles was 19,225. Of those individuals, 11,577 were excluded as they were <40 years old at the time of screening. Fourteen individuals were excluded because of missing information on preventive medications use.

2.2. Measurements

2.2.1. Outcome

The primary outcome was to determine the level of preventive medication use among adults in the US. The NHANES gives information on the prescription medication use reported by survey participants. The participants were asked “In the past 30 days, have you used or taken medication for which a prescription is needed?” The NHANES also provides information on the generic name of the drug, the duration of the use in days and the reasons for the use. Participants also reported whether they use low-dose preventive aspirin following medical advice or on their own. Preventive medication users were defined as those who reported using any medication to prevent any disease in the past 30 days or reported using low-dose preventive aspirin. In the analysis, this study did not differentiate between the acute use and chronic use of preventive medications. Furthermore, this study did not differentiate between primary prevention vs secondary prevention for diseases.

2.2.2. Explanatory Variables

The explanatory variables included demographic variables, chronic physical conditions and depression. The demographic variables were sex, age, race–ethnicity, marital status, education level, poverty, health insurance and smoking status. Age was categorized to four levels: 40–49, 50–64, 65–74 and ≥75 years. Race–ethnicity was categorized to Mexican Americans, other Hispanic, non-Hispanic white, non-Hispanic black and other. The marital status categories were married, living with partner, widowed, divorced, separated and never married. The poverty levels in the study were categorized as poor (poverty-ratio index < 100%) and non-poor. Health insurance levels were categorized as uninsured, private only, public only, private and public insurance and other. Smoking status was categorized as current smokers, past smokers and never smokers. Chronic physical conditions included arthritis (yes, no), diabetes (yes, no), heart disease (yes, no) and hypertension (yes, no). Other chronic physical conditions were asthma, emphysema, thyroid problems, chronic bronchitis, chronic obstructive pulmonary disease and cancer. The number of other chronic physical conditions was included in the analyses (no other
chronic physical conditions and ≥1 chronic physical conditions). Based on the scores of the Patient Health Questionnaire-9 (PHQ-9) scale, adults in the sample were categorized as adults with depression (score of 10 or greater) and adults without depression (score of less than 10). PHQ-9 is a widely used survey to measure depression, and it is based on nine items that generate scores from 0–27 [9].

2.3. Missing Data

The missing data for all of the explanatory variables, with the exclusion of depression, was 1.78% (N missing = 136), and 14% with the inclusion of depression (N missing = 1072). Missing data were associated with age, race, depression and heart disease. Separate analyses were run with depression and without depression as a sensitivity analysis. These analyses found no difference in the results.

2.4. Statistical Techniques

Weighted descriptive statistics were computed to calculate survey-weighted estimates of demographic characteristics and comorbidities. The NHANES cycle weights, survey strata and clusters were used to account for oversampling and non-response rates. The survey weights were divided by 2, as two cycles of the NHANES were merged. Chi-square tests were conducted to examine the associations between the explanatory variables and preventive medication use in the bivariate analysis. Since the main outcome of this study was binary (yes, no), multivariable logistic regression models were employed to examine the adjusted relationships between the explanatory variables and preventive medication use. Spearman correlation analysis showed very weak statistically significant correlation coefficients (ranging from −0.0024 to −0.29) between the explanatory variables, suggesting that there was no multicollinearity. The F-adjusted mean residual goodness-of-fit test for logistic regression estimated with survey sample data [10] was applied to assess the model fit. All analyses were conducted using survey procedures in STATA 16.0 (StataCorp, College Station, TX, USA).

3. Results

3.1. Description of the Study Sample

Table 1 shows the sample characteristics of the study sample. A total of 7634 individuals (weighted N = 150,830,186) aged 40 years or older are included in the present analysis. Of those, 31% use a preventive medication. Further, 53% of the sample are female, 68% are non-Hispanic White and 62% are married.

Table 1. Characteristics of the study sample’s preventive prescription medication use (N = 7634). Weighted percentages, National Health and Nutrition Examination Survey, 2015–2016, 2017–2018.
Table 1. Cont.

|                         | Aspirin Use and/or Other Preventive Medications | Aspirin Use Only | Other Preventive Medications |
|-------------------------|------------------------------------------------|------------------|-----------------------------|
|                         | All | No | Yes | p-Value | No | Yes | p-Value | No | Yes | p-Value |
| Race                    |     |    |     |         |    |     |         |    |     |         |
| Other Race              | 9   | 9.7| 8.6 | <0.001  | 9.7| 8.5 | <0.001  | 9.5| 8   | 0.034   |
| Marital Status          |     |    |     |         |    |     |         |    |     |         |
| Married                 | 62  | 62.8| 61.2| <0.001  | 62.5| 61.9| <0.001  | 62.3| 63.3| 0.010   |
| Widowed                 | 9   | 7  | 13.7| <0.001  | 7.4 | 13.5| <0.001  | 8.6 | 14.1|         |
| Divorced                | 14  | 14.3| 12.3|         | 14.3| 12.1|         | 14  | 10.6|         |
| Separated               | 3   | 2.7 | 2.6 |         | 2.7 | 2.6 |         | 2.7 | 2.4 |         |
| Never Married           | 7   | 7.3 | 6.3 |         | 7.4 | 6   |         | 7   | 6.8 |         |
| Living with Partner     | 5   | 5.9 | 3.9 |         | 5.8 | 3.9 |         | 5.5 | 2.7 |         |
| Education               |     |    |     | 0.042   |     | 0.064|         |     | 0.165|         |
| <High School            | 13  | 13.2| 14.1|         | 13.5| 13.3|         | 13.2| 15.9|         |
| High School             | 24  | 22.8| 25.9|         | 22.7| 26.7|         | 23.9| 22.3|         |
| Some College            | 31  | 30.6| 31.3|         | 31  | 30.4|         | 30.5| 34  |         |
| College +               | 32  | 33.4| 28.6|         | 32.8| 29.6|         | 32.3| 27.6|         |
| Poverty status          |     |    |     | 0.367   |     | 0.224|         |     | 0.830|         |
| Poor                    | 11  | 11.9| 10.6|         | 12  | 9.9 |         | 11.4| 12.3|         |
| Near-Poor               | 18  | 17.9| 19.9|         | 17.9| 20.1|         | 18.4| 19  |         |
| Middle Income           | 15  | 14.8| 15.2|         | 15  | 14.7|         | 14.9| 13.4|         |
| High Income             | 55  | 55.5| 54.4|         | 55.1| 55.3|         | 55.3| 53.2|         |
| Health insurance        |     |    |     | <0.001  |     | <0.001|         |     | <0.001|         |
| Private Only            | 45  | 52.8| 27.9|         | 51.3| 28.1|         | 47  | 25.3|         |
| Public Only             | 21  | 17.1| 30.3|         | 18  | 29.6|         | 19.9| 34  |         |
| Public and Private      | 17.2| 11.1| 30.9|         | 12.2| 30.9|         | 15.7| 32.7|         |
| Other                   | 7.5 | 7.9 | 6.6 |         | 7.7 | 6.8 |         | 7.8 | 4.3 |         |
| Uninsured               | 9   | 11.2| 4.3 |         | 10.8| 4.5 |         | 9.6 | 3.6 |         |
| Diabetes                |     |    |     |         |    |     |         |    |     |         |
| No                      | 84  | 90.9| 67.3| <0.001  | 89.4| 67.8| <0.001  | 85.8| 61.5| <0.001  |
| Yes                     | 16  | 9.1 | 32.7|         | 10.6| 32.2|         | 14.2| 38.5|         |
| Arthritis               |     |    |     | <0.001  |     | <0.001|         |     | <0.001|         |
| No                      | 61  | 67.4| 45.3|         | 66  | 46.1|         | 62.5| 41.3|         |
| Yes                     | 39  | 32.6| 54.7|         | 34  | 53.9|         | 37.5| 58.7|         |
| Hypertension            |     |    |     | <0.001  |     | <0.001|         |     | <0.001|         |
| No                      | 56  | 67  | 32.7|         | 65.1| 32.6|         | 58.9| 30.9| <0.001  |
| Yes                     | 44  | 33  | 67.3|         | 34.9| 67.4|         | 41.1| 69.1| <0.001  |
| Heart Disease           |     |    |     | <0.001  |     | <0.001|         |     | <0.001|         |
| No                      | 86  | 95.2| 66.4|         | 93.7| 66.3|         | 89.3| 55.3| <0.001  |
| Yes                     | 14  | 4.8 | 33.6|         | 6.3 | 33.7|         | 10.7| 44.7|         |
| Other Chronic Physical Conditions |     |    |     | <0.001  |     | <0.001|         |     | <0.001|         |
| None                    | 59  | 64  | 46.7|         | 62.7| 47.8|         | 60.3| 41.7| <0.001  |
| ≥1                      | 41  | 36  | 53.3|         | 37.3| 52.2|         | 39.7| 58.3| <0.001  |
| Depression              |     |    |     | 0.012   |     | 0.128|         |     | 0.005|         |
| No                      | 92  | 92.9| 90.6|         | 92.6| 91.1|         | 92.6| 87.7|         |
| Yes                     | 8   | 7.1 | 9.4 |         | 7.4 | 8.9 |         | 7.4 | 12.3|         |
| Smoking Status          |     |    |     | <0.001  |     | <0.001|         |     | 0.052|         |
| Never Smoker            | 54  | 55.8| 50.2|         | 55.7| 49.7|         | 54.2| 53.2|         |
| Currently Smoker        | 16  | 17.5| 12.4|         | 17  | 12.8|         | 16.3| 11.8|         |
| Past Smoker             | 30  | 26.7| 37.4|         | 27.3| 37.5|         | 29.5| 35  |         |

Wt.: weighted. Note: based on 7634 adults aged 40 years or over. The p-values were derived from chi-square tests between preventive medication users and non-users. Other chronic physical conditions include asthma, emphysema, thyroid problems, chronic bronchitis, chronic obstructive pulmonary disease and cancer.
Preventive medication use is significantly associated with sex, age, race, marital status, type of health insurance, diabetes, arthritis, hypertension, heart disease, presence of other chronic physical conditions, depression and smoking status in the bivariate analysis. Higher proportions of preventive medications users are aged 75 or older than non-preventive medications users (26% vs. 7%). Furthermore, higher proportions of preventive medications users have diabetes (33% vs. 9%), arthritis (55% vs. 33%), hypertension (67% vs. 33%), heart disease (34% vs. 5%) and depression (9% vs. 7%) than those who are non-preventive medications users.

3.2. Explanatory Variables and Preventive Prescription Medications Use

The F-adjusted mean residual goodness-of-fit test was applied and suggests no evidence of lack-of-fit of the logistic regression model (adjusted $F = 1.336$, df = 9, 22, $p$-value = 0.275). The adjusted odds ratios and their 95% confidence interval (CI) for the explanatory variables on preventive prescription medications are displayed in Table 2. In the adjusted analyses, adults between 65–74 years old are significantly more likely to use preventive medications as compared with those 40–49 years of age. Similarly, adults aged 75 years or over are more likely to use preventive medications than those between 40–49 years old. Additionally, females are less likely than males to use preventive medications. Conversely, there is no relationship between race and preventive medication use found in the adjusted analyses.

Table 2. Adjusted odds ratios (AOR) and their 95% confidence intervals (CI) of the explanatory variables from multivariable logistic regression on preventive prescription medication use, National Health and Nutrition Examination Survey, 2015–2016, 2017–2018.

|                          | AOR      | 95% CI               | $p$-Value |
|--------------------------|----------|----------------------|-----------|
| **Sex**                  |          |                      |           |
| Male                     | 0.746    | (0.628–0.885)        | 0.001     |
| Female                   | Reference (1) |                      |           |
| **Age Groups**           |          |                      |           |
| 40–49                    | 2.616    | (1.947–3.514)        | <0.001    |
| 50–64                    | 4.271    | (2.869–6.358)        | <0.001    |
| ≥75                      | 6.985    | (4.632–10.532)       | <0.001    |
| **Race–Ethnicity**       |          |                      |           |
| Non-Hispanic White       | 0.995    | (0.777–1.274)        | 0.966     |
| Mexican Americans        | 0.882    | (0.65–1.197)         | 0.408     |
| Other Hispanic           | 0.918    | (0.747–1.127)        | 0.4       |
| Black                    | 0.843    | (0.678–1.048)        | 0.12      |
| **Marital Status**       |          |                      |           |
| Married                  | 0.648    | (0.484–0.868)        | 0.005     |
| Widowed                  | 0.771    | (0.585–1.015)        | 0.063     |
| Divorced                 | 1.131    | (0.63–2.029)         | 0.671     |
| Separated                | 1.083    | (0.612–1.919)        | 0.777     |
| Never Married            | 0.674    | (0.494–0.92)         | 0.015     |
| Living with Partner      |          |                      |           |
| **Health Insurance**     |          |                      |           |
| Private Only             | 1.075    | (0.846–1.365)        | 0.542     |
| Public Only              | 1.393    | (0.946–2.052)        | 0.091     |
| Public and Private       | 1.182    | (0.906–1.543)        | 0.21      |
| Other                    | 0.656    | (0.483–0.892)        | 0.009     |
| Uninsured                |          |                      |           |
Table 2. Cont.

| Smoking Status       | AOR    | 95% CI          | p-Value |
|----------------------|--------|-----------------|---------|
| Currently Smoker     | 1.431  | (1.065–1.922)   | 0.019   |
| Past Smoker          | 1.423  | (1.053–1.922)   | 0.023   |
| Never Smoker         | 1.423  | (1.053–1.922)   | 0.023   |

| Diabetes             |        |                 |         |
|----------------------|--------|-----------------|---------|
| No                   | 2.779  | (2.097–3.684)   | <0.001  |
| Yes                  | 1.344  | (1.052–1.717)   | 0.020   |

| Arthritis            |        |                 |         |
|----------------------|--------|-----------------|---------|
| No                   | 1.344  | (1.052–1.717)   | 0.020   |
| Yes                  | 2.294  | (1.951–2.726)   | <0.001  |

| Hypertension         |        |                 |         |
|----------------------|--------|-----------------|---------|
| No                   | 2.294  | (1.951–2.726)   | <0.001  |
| Yes                  | 5.504  | (4.388–6.905)   | <0.001  |

| Heart Disease        |        |                 |         |
|----------------------|--------|-----------------|---------|
| No                   | 1.188  | (0.988–1.429)   | 0.067   |
| Yes                  | 5.504  | (4.388–6.905)   | <0.001  |

| Other Chronic Physical Conditions |        |                 |         |
|----------------------------------|--------|-----------------|---------|
| None                             | 1.188  | (0.988–1.429)   | 0.067   |
| ≥1                                | 5.504  | (4.388–6.905)   | <0.001  |

AOR: adjusted odds ratio. Note: based on 7634 adults aged 40 years or over. Other chronic physical conditions include asthma, emphysema, thyroid problems, chronic bronchitis, chronic obstructive pulmonary disease and cancer.

Uninsured adults aged 40 years or older are less likely to use preventive prescription medications compared with their counterparts with private insurance. Additionally, past smokers and never smokers are more likely to use preventive medications than currently smokers.

All chronic physical conditions are significantly and positively associated with preventive prescription medication use. Adults with diabetes are more likely to use preventive medications than those without. Similarly, adults with heart disease are more likely to use preventive prescription medications than those without. Additionally, those with arthritis, hypertension and a number of other chronic physical conditions are also more likely to use preventive medications.

3.3. Preventive Prescription Medications

Figure 1 shows the weighted percentages of prescription medications (other than aspirin use) by therapeutic medication class. From 2015–2018, 27% of the preventive prescription medication users reported using one of the cardiovascular agents as a prevention therapy. Specifically, 10% of them reported using beta-adrenergic-blocking agents and 9% reported using angiotensin-converting enzyme inhibitors. Additionally, 24% reported using coagulation modifiers (anticoagulants and/or antiplatelet agents). Furthermore, 22% reported using metabolic agents, including antihyperlipidemic agents (16%). Of the preventive prescription medications users, 6% used anti-infectives to prevent bacterial infection.

3.4. Primary Reasons for Using Preventive Prescription Medications

Figure 2 lists the most-reported primary reasons for using preventive prescription medications. One quarter of the preventive prescription medication users reported preventing heart attacks/myocardial infarctions the primary reason for using preventive medication therapy. Furthermore, 23% of them reported preventing blood clots as the primary reason for preventive medication therapy.
Healthcare 2022, 10, x FOR PEER REVIEW ... prevent cardiovascular disease was deemed helpful for a long time [13]. Nevertheless, the US Preventive Services Task Force recommends screening and counseling to improve cardiovascular health among adults. Therefore, preventive medication therapy is an important strategy to reduce disease and complications related to cardiovascular disease. Medications including antiplatelets, angiotensin enzyme inhibitors, and/or anticoagulants are used due to their beneficial effects on cardiovascular disease. Furthermore, 23% of them reported preventing blood clots as the primary reason for preventive medication therapy.

![Figure 1. Weighted percentages of prescription medications by therapeutic medication class (N: 1072).](image1)

![Figure 2. Weighted percentages of reported primary reasons for using preventive prescription medications (N: 995).](image2)
4. Discussion

This study examines the associations between demographic, socioeconomic and clinical factors and preventive prescription medication use among adults aged 40 years or older in the US. In the adjusted analyses, older age and the presence of chronic physical conditions are associated with the use of preventive prescription medications. These results suggest that preventive prescription medications are mainly used as a secondary prevention strategy to prevent complications of existing chronic physical conditions.

The results also suggest that uninsured adults have lower access to medications. In 2015, adults without health insurance were less likely to use preventive aspirin and/or other antiplatelets medications in the US [4]. In 2019, uninsured adults were more likely to not receive prescription medications due to cost as compared with their counterparts with private or public insurance [11]. Furthermore, uninsured adults with chronic conditions were less likely to receive the recommended follow-up services, including preventive care. Preventive care, including preventive prescription medications and follow-up care, is important to prevent disease-related complications and improve the physical and mental health of adults with chronic conditions. Furthermore, Ito et al. found that increasing access to preventive medications, including β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins and aspirin, to post-myocardial infarction patients improves health outcomes and also decreases healthcare spending over the long-term [12]. Therefore, policies and programs are required to improve access to preventive care among uninsured adults, especially among those with chronic physical complications.

The results show that older adults are more likely to use preventive medications. Preventive medication use is an effective strategy to prevent disease-related complications, as well as to stop the progress of chronic physical conditions. However, further research is required to determine the benefits and harms of preventive medication use, especially among older adults. For example, aspirin use to prevent cardiovascular disease was deemed helpful for a long time [13]. Nevertheless, the US Preventive Services Task Force (USPSTF) concluded that the net benefit of using preventive aspirin for adults aged 40 to 59 years is small [14]. Furthermore, the USPSTF recommends against initiating aspirin use for the primary prevention of cardiovascular disease in adults 60 years of age or older [14]. Additionally, older adults usually use a high number of long-term medications [15]. Unfortunately, older adults are often excluded from randomized clinical trials. As a result, the benefits and drawbacks of the chronic use of preventive prescription medications are unclear. Therefore, it has been recommended that prescribers should pay more attention and minimize the number of medications among older adults with multimorbid conditions [15].

The foremost consideration for the appropriate use of drugs in a preventive manner would be the strict adherence to the recent changes in clinical guidelines. For example, from 2011–2018, the prevalence of aspirin use among older US adults (≥60 years) was high among individuals at an increased risk for bleeding and other adverse events [16], despite recent changes in the guidelines of the American Heart Association, American Diabetes Association and USPSTF. Moreover, other considerations should be considered before the initiation or continuation of preventive medications use, such as age, multimorbidity, number of other medications and updated guidelines. Furthermore, healthcare professionals need to discuss the benefits and harms of preventive medication use with their patients. Finally, a comprehensive review of preventive medication use in the US is required to determine the net benefits of the use and to determine the consistency of the use with current guidelines.

In this study, current smokers were less likely to use preventive medications. This finding is consistent with previous reports in which smoking status is a risk factor for not receiving eye care and other preventive practices among adults with diabetes [17–19]. Smoking is a risk factor of multiple chronic conditions and their related complications. Therefore, it is crucial to understand the low prevalence of preventive practices among smoking adults. Furthermore, it is required to increase the rate of preventive health practices among smoking adults.
This study has many advantages. First, to the best of the author’s knowledge this is the first study to comprehensively review the preventive prescription medication use among adults in the US. Second, this study includes a comprehensive list of clinical, socioeconomic and demographic factors that may affect preventive medications use. Finally, a nationally representative sample of adults aged 40 years or above was included to estimate the prevalence of preventive prescription medication use. Nevertheless, this study has some limitations. This study did not differentiate between chronic and acute preventive medication use. Furthermore, other over-the-counter and non-prescription preventive medications (excluding aspirin) were not included in the analyses of this study.

5. Conclusions

More than one-third of adults aged 40 years or older used a preventive medication from 2015–2018 in the US. The majority of the study sample used low-dose preventive aspirin. Uninsured adults were less likely to use preventive medications. Nevertheless, older adults and those with chronic physical conditions were more likely to use preventive medications. Strategies are needed to increase the access to preventive care for uninsured adults. Further research needs to review the preventive prescription medications used in the US.

Funding: This research received no external funding.

Institutional Review Board Statement: Ethical review and approval were waived for this study because it did not involve humans or animals.

Informed Consent Statement: Not applicable. the National Health and Nutrition Examination Survey (NHANES) data are published openly https://www.cdc.gov/nchs/nhanes/ (accessed on 5 February 2022). The information on the participants was fully anonymized and unidentified prior to analysis.

Data Availability Statement: This study was based on a publicly available dataset, NHANES, and can be obtained directly from https://www.cdc.gov/nchs/nhanes/ (accessed on 5 February 2022).

Conflicts of Interest: The author declares no conflict of interest.

References

1. Gu, Q.; Paulose-Ram, R.; Burt, V.L.; Kit, B.K. Prescription Cholesterol Lowering Medication Use in Adults Aged 40 and Over: United States, 2003–2012; National Center for Health Statistics: Hyattsville, MD, USA, 2014.
2. Wang, K.; Li, Y.; Liu, G.; Rimm, E.; Chan, A.T.; Giovannucci, E.L.; Song, M. Healthy Lifestyle for Prevention of Premature Death Among Users and Nonusers of Common Preventive Medications: A Prospective Study in 2 US Cohorts. J. Am. Heart Assoc. 2020, 9, e016692. [CrossRef] [PubMed]
3. Williams, C.D.; Chan, A.T.; Elman, M.R.; Kristensen, A.H.; Miser, W.F.; Pignone, M.P.; Stafford, R.S.; McGregor, J.C. Aspirin use among adults in the US: Results of a national survey. Am. J. Prev. Med. 2015, 48, 501–508. [CrossRef] [PubMed]
4. Gu, Q.; Dillon, C.F.; Eberhardt, M.S.; Wright, J.D.; Burt, V.L. Preventive aspirin and other antiplatelet medication use among US adults aged ≥ 40 years: Data from the National Health and Nutrition Examination Survey, 2011–2012. Public Health Rep. 2015, 130, 643–654. [CrossRef] [PubMed]
5. Owens, D.K.; Davidson, K.W.; Krist, A.H.; Barry, M.J.; Cabana, M.; Caughey, A.B.; Doubeni, C.A.; Epling, J.W., Jr.; Kubik, M.; Landefeld, S.C.; et al. Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement. JAMA 2019, 322, 857–867. [PubMed]
6. D’Amico, D.; Tepper, S.J. Prophylaxis of migraine: General principles and patient acceptance. Neuropsychiatr. Dis. Treat. 2008, 4, 1155. [CrossRef] [PubMed]
7. McCombs, J.S.; Thiebaud, P.; McLaughlin-Miley, C.; Shi, J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004, 48, 271–287. [CrossRef] [PubMed]
8. Padwal, R.; Majumdar, S.R.; Johnson, J.A.; Varney, J.; McAlister, F.A. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005, 28, 736–744. [CrossRef]
9. Kroenke, K.; Spitzer, R.L.; Williams, J.B. The PHQ-9: Validity of a brief depression severity measure. J. Gen. Intern. Med. 2001, 16, 606–613. [CrossRef]
10. Archer, K.J.; Lemeshow, S. Goodness-of-fit test for a logistic regression model fitted using survey sample data. Stata J. 2006, 6, 97–105. [CrossRef]
11. Tolbert, J.; Orgera, K.; Damico, A. Key Facts about the Uninsured Population. Henry J Kaiser Family Foundation. 2020. Available online: https://www.kff.org/uninsured/issue-brief/key-facts-about-the-uninsured-population/ (accessed on 5 February 2022).

12. Ito, K.; Avorn, J.; Shrank, W.H.; Toscano, M.; Spettel, C.; Brennan, T.; Choudhry, N.K. Long-term cost-effectiveness of providing full coverage for preventive medications after myocardial infarction. Circ. Cardiovasc. Qual. Outcomes 2015, 8, 252–259. [CrossRef] [PubMed]

13. Rhee, T.G.; Kumar, M.; Ross, J.S.; Coll, P.P. Age-related trajectories of cardiovascular risk and use of aspirin and statin among US adults aged 50 or older, 2011–2018. J. Am. Geriatr. Soc. 2021, 69, 1272–1282. [CrossRef] [PubMed]

14. Guirguis-Blake, J.M.; Evans, C.V.; Perdue, L.A.; Bean, S.I.; Senger, C.A. Aspirin use to prevent cardiovascular disease and colorectal cancer: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2022, 327, 1585–1597. [CrossRef] [PubMed]

15. Van Middelaar, T.; van Charante, E.P.M. Deprescribing preventive medication in older patients. Br. J. Gen. Pract. 2018, 68, 456–457. [CrossRef] [PubMed]

16. Liu, E.Y.; Al-Sofi an, M.E.; Yeh, H.-C.; Echouffo-Tcheugui, J.B.; Joseph, J.J.; Kalyani, R.R. Use of preventive aspirin among older us adults with and without diabetes. JAMA Open 2021, 4, e2112210. [CrossRef] [PubMed]

17. Murchison, A.P.; Hark, L.; Pizzi, L.T.; Dai, Y.; Mayro, E.L.; Storey, P.P.; Leiby, B.E.; Haller, J.A. Non-adherence to eye care in people with diabetes. BMJ Open Diabetes Res. Care 2017, 5, e000333. [CrossRef] [PubMed]

18. Centers for Disease Control and Prevention. Prevalence of receiving multiple preventive-care services among adults with diabetes—United States, 2002–2004. MMWR. Morb. Mortal. Wkly. Rep. 2005, 54, 1130–1133.

19. Meraya, A.M.; Makeen, H.A. Self-reported receipt of preventive practices and its associated factors among adults with diabetes in the United States. Prev. Med. Rep. 2019, 14, 100857. [CrossRef] [PubMed]